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Abstract - Mass vaccination has significantly reduced the incidence of pertussis, however, the disease is re-emerging, even 
in some countries with high vaccination coverage. In Serbia, whole cell pertussis vaccine was introduced in 1957. To moni-
tor changes in bacterial population, 77 isolates collected from 1953 to 2011 were studied. The methods included serotyp-
ing of fimbriae (Fim), genotyping of pertactin (prn) and pertussis toxin S1 subunit (ptxA). A shift from ptxA2 to ptxA1 
has been observed in isolates since the late of 1960s. In the period 1961-1979, the genotype ptxA1 became as common as 
genotype ptxA2. After that, during the period 1980-1989, the predominant ptx genotype was ptxA1. The reappearance 
of the ptxA2 allele followed an addition of the two strains harboring ptxA1 in the vaccine in 1985. The allele prn1 was 
predominant among the Serbian isolates, though prn3 and prn11 have been detected since 1981. The prn2 allele was only 
found in one strain isolated in 1984, two of the four strains isolated in 2000 and in three isolated strains from 2011. Sero-
type Fim2.3 disappeared before 1980 and serotype Fim2 became predominant thereafter. The results of this study indicate 
that the B. pertussis population in Serbia is different from other vaccinated populations and that this difference may be 
related to the vaccine used.
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INTRODUCTION
Pertussis  (whooping  cough)  is  a  worldwide  infec-
tious disease caused by the bacteria Bordetella per-
tussis (Miller et al., 1992). Despite the fact that the 
introduction of vaccination in the 1950s and 1960s 
has reduced pertussis morbidity and mortality, this 
disease is still prevalent (Mattoo and Cherry, 2005) 
and pertussis is still one of the leading causes of vac-
cine-preventable deaths in the world (WHO, 2012). 
Pertussis is a respiratory tract infection transmitted 
by aerial droplets, with an incubation period of 7-10 
days, which remains contagious for up to 3 weeks af-
ter the appearance of the first signs if no treatment 
is given. Mass vaccination has significantly reduced 
the incidence of pertussis; however, the disease is 
re-emerging even in some countries with high vac-
cination  coverage.  The  resurgence  of  pertussis  in 
countries such as the Netherlands, the United States, 
Canada and Australia, has been studied to find an ex-
planation for its re-emergence (Cassiday et al., 2000; 
Mattoo and Cherry, 2005; Byrne and Slack, 2006; de 
Greeff et al., 2010, Celentano et al., 2005). Moreover, 
in these countries antigenic divergence with respect 
to pertussis toxin (Ptx) and pertactin (Prn) has been 
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and clinical isolates. In Serbia, vaccination against 
pertussis has been implemented for 50 years. The 
diphtheria-tetanus-whole cell pertussis (DTPw) vac-
cine has been manufactured in the Institute of Virol-
ogy, Vaccine and Sera Torlak, Belgrade, Serbia since 
1957. The DTPw vaccine is given at 2, 4, 6, and 12 
months of age. A second booster dose with the mono 
pertussis vaccine was given at the age of 4 years dur-
ing the periods from 1970 to 1981 and from 1990 to 
2000. The current composition of the vaccine has been 
used since 1985 and contains four B. pertussis strains. 
The vaccine strains were chosen in compliance with 
serotype, immunogenicity and specific toxicity. The 
four strains represent three serotypes: Fim2 (8/84), 
Fim2.3  (1772/57  and  2047/57)  and  Fim3  (23/81). 
The vaccine strains 2047/57 and 1772/57 represent 
ptxA2/prn1 genotypes, whereas the vaccine strains 
23/81 and 8/84 harbor ptxA1/prn1 and ptxA1/prn2. 
All vaccine strains are in equal amount in the vaccine 
composition (Dakic et al., 2010). The reported vac-
cination coverage in Serbia ranged from 79% to 98% 
(median, 90%) in 1981-2011 (WHO, 2012). The aim 
of this study was to analyze B. pertussis isolates circu-
lating between 1953 and 2011 in Serbia by standard 
typing methods (Mooi et al., 2000) and to compare 
them to those circulating in other European coun-
tries, USA and Australia. 
MATERIALS AND METHODS
B. pertussis strains and patient information
This study included 77 B. pertussis isolates. Detailed 
information on each of vaccine strain and clinical 
isolates is included in the Supplementary Data. Clin-
ical isolates were selected from the B. pertussis strain 
collection of the Institute of Virology, Vaccine and 
Sera Torlak, Belgrade, Serbia. Information on age, 
gender and vaccination was available for 64 patients. 
Their age ranged from 2 months to 33 years (mean, 
6.06 years; median, 5 years)
Bacteria were grown at 36°C for 72 h on Bordet 
Gengou agar supplemented with 30% defibrinated 
sheep blood and subcultured on the same medium 
for 24 h (Bouchez et al., 2008). 
Fimbriae serotyping of B. pertussis isolates
Serotyping  was  performed  with  monoclonal  anti-
bodies against Fim2 and Fim3 by slide agglutination 
test (Advani et al., 2004; Mooi et al., 2000)
Genotyping of Ptx S1 subunit (ptxA) and prn
The  standardized  genotyping  of  Ptx  S1  subunit 
(ptxA) and prn was performed by sequencing and 
LightCycler PCR (Advani et al., 2004; Elomaa et al., 
2005; Heikkinen et al., 2008). These methods have 
been recommended for the epidemiological typing 
of B. pertussis isolates (Mooi et al., 2000). 
Statistical analysis
The chi-square test was used to compare frequen-
cies of strain genotypes and serotypes between four 
time-periods (1953-1960, 1961-1979, 1980-1989 and 
1990-2011). A p-value ≤0.05 was considered statisti-
cally significant. Selection of time-periods was per-
formed according to the epidemiological data. 
RESULTS
Epidemiology of pertussis in Serbia
In Serbia, pertussis is a notifiable infectious disease, 
which is collected in the Infectious Disease Register 
of the National Public Health Institute. The incidence 
of pertussis in Serbia has been decreasing since the 
introduction of vaccination at the end of the 1950s 
and beginning of the 1960s (Fig. 1). All isolates prior 
to 1960 were recovered from unvaccinated patients. 
In the period 1980-1989, 82.35% of patients were 
vaccinated while 64.3% were vaccinated in the period 
1990-2011. There were no epidemiological data for 
strains isolated from patients in period 1960-1979.
Fimbriae serotyping
All three serotypes, Fim2, Fim2.3, and Fim3 were 
observed among the clinical isolates (Supplementary 
Data). The frequency of each serotype has changed 
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the prevalent serotypes were Fim2 (38%) and Fim2.3 
(62%).  After  the  introduction  of  vaccination,  the 
frequency of serotype Fim2.3 decreased, being sig-
nificantly lower (0% in 1980-1989 and 23% in 1990-
2011)  compared  to  those  observed  in  1953-1960 
and 1961-1979 (P = 0.00013 and 0.0003) (Table 1). 
Although the serotype Fim3 started to appear, Fim2 
has  been  the  most  prevalent  serotype  during  the 
study period.
Genotypes of ptxA and prn
All strains isolated from 1953 to 1960 were of ptxA2 
genotype. A shift from ptxA2 to ptxA1 has been ob-
served in isolates since the late 1960s. In the period 
1961-1979, the genotype ptxA1 became as common 
as  genotype  ptxA2.  After  that,  during  the  period 
1980-1989, the predominant ptx genotype was ptxA1 
(91.2%).  The  re-appearance  of  isolates  containing 
ptxA2 was noticed after the two strains harboring 
ptxA1 were added into the vaccine in 1985 (Dakic 
et al., 2010). During the period of 1990-2011, both 
ptxA genotypes were present in the population.
In  the  first  two  observed  periods,  1953-1960 
and 1960-1979, all isolated strains were of the prn1 
genotype. Although the allele prn1 was mostly pre-
dominant among the Serbian isolates analyzed (Sup-
plementary Data), prn2, prn3 and prn11 occurred 
in some isolates since the 1980s and finally the prn2 
genotype became predominant in the period 1990-
2011. The alleles prn3 and prn11 were first detected 
in 1981 and 1984, respectively, and became more fre-
quent in 1990-2011. The prn2 allele was only found 
in one strain isolated in 1984, two of the four strains 
isolated in 2000 and three isolated strains from 2011. 
The frequency of prn1 in 1953-1960 and 1961-1979 
was significantly higher than that observed in 1980-
1989 and 1990-2011 (P <0.001 in both groups) (Table 
1). The frequency of prn11 in 1980-1989 and 1990-
2011 was significantly higher than that found in 1953-
1960 and 1961-1979 (P <0.001 in both groups). 
All four isolates harboring prn3 contained ptxA1, 
whereas five of the six isolates harboring prn11 con-
tained ptxA2. All six isolates harboring prn11 were 
serotype Fim2, whereas three of the four isolates har-
boring prn3 were serotype Fim3. 
DISCUSSION
Vaccinations  with  Pw  vaccines  were  introduced 
Fig. 1. The incidence (cases per 100 000) of reported pertussis cases in Serbia between 1965 and 2011. Source: Infectious Disease Regis-
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SUPPLEMENTARY DATA
Strain
code
Gender Age (years)
Vaccination
Status
Serotype Prn PtxA
Year of
isolation
Note
22/53 f 5 no 2 1 2 1953
124/54 N.A. N.A. no 2 1 2 1954
162/54 m 8 no 2,3 1 2 1954
177/54 m 7 no 2,3 1 2 1954
200/54 f 4 no 2,3 1 2 1954
38/54 f 7 no 2 1 2 1954
40/54 m 5 no 2 1 2 1954
515/55 N.A. N.A. N.A. 2 1 2 1955
1078/56 f 2.5 no 2,3 1 2 1956
1499/56 N.A. N.A. N.A. 2,3 1 2 1956
1496/57 N.A. N.A. no 2 1 2 1957
1611/57 f 3 no 2 1 2 1957
1714/57 m 4.5 no 2,3 1 2 1957
1772/57 N.A. N.A. N.A. 2,3 1 2 1957
vaccine strain 
since 1972
1828/57 f 4 months no 2,3 1 2 1957
1881/57 N.A. N.A. no 2,3 1 2 1957
2047/57 N.A. N.A. N.A. 2,3 1 2 1957
vaccine strain 
since 1968
2048/57 m 6 no 2 1 2 1957
1997/58 m 4.5 no 2,3 1 2 1958
2154/58 f 7 no 2,3 1 2 1958
3008/60 N.A. N.A. N.A. 2,3 1 2 1960
33/69 N.A. N.A. N.A. 3 1 1 1969
90/69 N.A. N.A. N.A. 2,3 1 2 1969
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Strain
code
Gender Age (years)
Vaccination
Status
Serotype Prn PtxA
Year of
isolation
Note
122/69 N.A. N.A. N.A. 2,3 1 2 1969
258/70 N.A. N.A. N.A. 2,3 1 2 1970
487/71 N.A. N.A. N.A. 2,3 1 2 1971
375/71 N.A. N.A. N.A. 2,3 1 1 1971
849/73 N.A. N.A. N.A. 3 1 1 1973
885/73 N.A. N.A. N.A. 3 1 1 1973
55145/80 N.A. N.A. N.A. 3 1 1 1980
59377/80 N.A. N.A. N.A. 3 1 1 1980
23/81 f 3 yes, no booster 3 1 1 1981
vaccine strain 
since 1985
29/81 m 6 yes 3 1 1 1981
30/81 f 3 yes 3 3 1 1981
32/81 m 9 months 1 dose 3 1 1 1981
40311/81 f 7 yes 3 1 1 1981
1/84 m 6 yes, no booster 2 1 1 1984
2/84 f 6 yes 2 1 1 1984
3/84 f 4 yes 2 1 1 1984
4/84 f 6 yes 2 1 1 1984
5/84 m 6 yes 2 3 1 1984
6/84 m 1 yes 2 1 1 1984
7/84 f 5 yes 2 1 1 1984
8/84 m 4 months no 2 2 1 1984
vaccine strain 
since 1985
9/84 f 33 yes 2 1 1 1984
10/84 m N.A. no 2 1 1 1984
11/84 m 1 no 3 1 1 1984
12/84 m 1 yes 2 1 1 1984
SUPPLEMENTARY DATA continued112 TATJANA PLJEŠA ET AL.
Strain
code
Gender Age (years)
Vaccination
Status
Serotype Prn PtxA
Year of
isolation
Note
14/84 m 13 yes 2 1 1 1984
15/84 m 2 yes 2 1 1 1984
17/84 m 12 yes 2 1 1 1984
18/84 m 16 months 2 doses 2 1 1 1984
20/84 f 5 yes 3 11 1 1984
21/84 f 10 yes 2 1 1 1984
22/84 m 9 yes 3 1 1 1984
24/84 f 4 yes 3 1 1 1984
28/85 m 6 yes 2 1 1 1985
50042/86 m 2 no 2 11 2 1986
52121/86 m 3 months no 2 1 1 1986
9783/87 f 4.5 yes 2 1 2 1987
28270/89 f 10 yes 2 11 2 1989
28756/89 f 9 yes 3 3 1 1989
28928/89 f 6 yes 2 1 1 1989
12/90 m 11 yes 2 11 2 1990
51651/90 m 10 yes 2 11 2 1990
52376/90 f 11 yes 2 1 1 1990
53367/90 f 9 yes 2 1 1 1990
9420/90 m 12 yes 2 1 1 1990
53746/91 m 6 months 1 dose 2 1 1 1991
1/00 m 13 yes 2 11 2 2000
6/00 m 1.5 2 doses 3 3 1 2000
7/00 m 9 yes 3 2 1 2000
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from  the  1940s  to  the  1960s.  They  have  success-
fully  reduced  morbidity  and  mortality  from  per-
tussis throughout the world (He et al., 2008). Pw 
vaccines  have  been  produced  by  different  manu-
facturers, and the B. pertussis vaccine strains vary. 
The vaccine strains, both for whole-cell and acel-
lular vaccines, were isolated from the 1940s to the 
1960s, and in many countries the vaccinations have 
selected circulating isolates that were dissimilar to 
the vaccine strains (Elomaa et al., 2005; Cassiday et 
al., 2000; Mooi et al., 1999, Kallonen et al., 2011). 
Furthermore, the resurgence of pertussis has been 
observed in countries with long-term pertussis vac-
cination  (Cellentano  et  al.,  2005;  Halperin  et  al., 
2007; McIntyre et al., 2002; Mooi et al., 2001, Ka-
llonen et al., 2011). In Serbia, the Pw vaccine has 
been in use from 1957 and is manufactured in the 
Institute of Virology, Vaccines and Sera Torlak, Bel-
grade. In contrast to the many other countries, the 
Serbian vaccine contains four strains: two isolated in 
the 1950s and two in the 1980s. Of the four strains, 
one strain carries the prn2 genotype and the other 
three the prn1 genotype. The vaccine has remained 
unchanged  since  1985,  when  two  newly  isolated 
strains were added to the vaccine composition. One 
of the added strains was strain 8/84 with the prn2 
allele (Dakic et al., 2010). This unique formulation 
of the Serbian Pw vaccine provided us an opportu-
nity to study the possible effect of the inclusion of 
“contemporary” strains in the vaccine on temporal 
trends in the B. pertussis population. The discovery 
that the frequency of Serbian isolates representing 
SUPPLEMENTARY DATA continued
Strain
code
Gender Age (years)
Vaccination
Status
Serotype Prn PtxA
Year of
isolation
Note
8/00 m 12 yes 3 2 1 2000
2/11 m 2.5 months no 2,3 2 1 2011
3/11 f 2,5 no 2,3 2 1 2011
5/11 m 2 months no 2,3 2 1 2011
Abbreviations:
N.A.: not available
m: male
f: female
Table 1. Temporal trends in serotypes and genotypes of pertussis toxin and pertactin in Serbia.
Year of  
isolation
No of 
isolates
ptxA (no) prn (no) serotype (no)
ptxA1 ptxA2 prn1  prn2  prn3  prn 11 Fim2 Fim2,3 Fim3
1953-1960 21 0 21 21 0 0 0 8 13 0
1961-1979 9 4 5 9 0 0 0 0 6 3
1980-1989 34 31 3 27 1 3 3 22 0 12
1990-2011 13 10 3 4 5 1 3 7 3 3
Total 77 45 32 61 6 4 6 37 22 18114 TATJANA PLJEŠA ET AL.
prn2 was low and its appearance was late, is striking. 
Polymorphism in Prn is essentially limited to re-
gion 1 and is located adjacent to an RDG motif im-
plicated in adhesion (Leininger et al., 1991). So far, 
13 prn alleles have been identified (Mooi, 2010). In 
many countries, the allele prn1 or prn7 is present in 
most vaccine strains and predominated in the pre-
vaccine era (He et al., 2008). However, the “vaccine 
type” strains were gradually replaced by “non-vac-
cine type” strains, mainly prn2, after the introduc-
tion of vaccination. Prn2 is by far the most prevalent 
type in modern isolates (Advani et al., 2004; Elomaa 
et al., 2005; Cassiday et al., 2000; Mooi et al., 1998; 
Weber et al., 2001; Njamkepo et al., 2008; Kallonen 
et al., 2011 ). Depending on the time when pertus-
sis vaccination was started and the potency of the 
vaccine used, in most countries isolates containing 
prn2 were first observed from the 1970s to the 1980s 
(Advani et al., 2004; Elomaa et al., 2005; Cassiday 
et al., 2000; Mooi et al., 1998; Weber et al., 2001; 
Hallander et al., 2005). In line with these observa-
tions, in Serbia one isolate (8/84) harboring prn2 
was detected in 1984. The isolate was added to the 
vaccine composition in 1985. After that, all isolates 
were prn1 or prn11 until 2000, when two out of four 
isolates contained the prn2 allele. The low frequency 
of prn2 strains and their relatively late emergence 
in Serbia may be because the vaccine contains an 
isolate with a prn2 allele. In this present study, four 
different prn alleles (prn1, prn2, prn3 and prn11) 
were detected among the Serbian isolates. The al-
leles prn1-3 have been observed in many countries 
(Elomaa et al., 2005; Cassiday et al., 2000; Mooi et 
al., 1998; Weber et al., 2001; Poynten et al., 2004; 
Njamkepo et al., 2008). The allele prn11 was only 
reported in a recent study carried out in Australia, 
where all five strains containing prn11 were isolated 
in the same year (1982) and the same region (Poynt-
en et al., 2004). However, in our study, the six prn11 
isolates were detected in different years from 1984 to 
2000. Of the six isolates, four had identical serotypes 
and the ptxA genotype. The difference between Prn1 
and Prn11 was only one repeat in region 1. Prn1 has 
five repeats, whereas Prn11 has six repeats. The ob-
servation that most of the isolates from 1980 to 2011 
contained the prn1 or prn11 allele suggested that 
the strains prevalent in the pre-vaccine era are still 
circulating in Serbia. The Serbian vaccine strains do 
not contain the allele prn3. However, strains harbor-
ing the prn3 allele were not isolated in the study at 
a frequency comparable to that seen in other coun-
tries (Elomaa et al., 2005; Mooi et al., 1998; Poynten 
et al., 2004; Njamkepo et al., 2008 ) The exact rea-
sons for the difference are not known. In addition 
to the vaccine composition, many factors such as 
immunity, density and dynamics of population can 
contribute to selection of the circulating strains. So 
far,  eight  ptxA  alleles  have  been  reported  (Mooi, 
2010). In most countries, the allele ptxA2 and/or 
ptxA3 are present in most vaccine strains and pre-
dominated in the isolates circulating in pre-vaccine 
era (Elomaa et al., 2005; Cassiday et al., 2000; We-
ber  et  al.,  2001;  Kallonen  et  al.,  2011).  However, 
the “vaccine type” strains were gradually replaced 
by “non-vaccine” type ptxA1 after vaccination was 
introduced. Our result is in agreement with earlier 
studies. A shift from ptxA2 to ptxA1 was observed 
in isolates since the late 1960s, and the predominant 
ptxA genotype in the period 1980-1989 was ptxA1. 
Interestingly, the reappearance of the ptxA2 allele 
followed an addition of the two strains harboring 
ptxA1  to  the  vaccine  composition  in  1985.  After 
that moment, there were more ptxA2 isolates than 
previously. The high frequency of strains harboring 
ptxA2 in 1990-2011 was not comparable to that no-
ticed in many other countries (Elomaa et al., 2005; 
Cassiday et al., 2000; Weber et al., 2001). Several 
studies have shown that Fim2 isolates predominate 
in unvaccinated populations, while they are largely 
displaced by Fim3 strains when vaccination is intro-
duced with a Pw vaccine containing both Fim2 and 
Fim3 (Hallander et al., 2007; Preston et al., 1992). 
Although  vaccination  has  been  implemented  in 
Serbia since 1957, nearly half of the isolates studied 
from 1957 to 2011 were serotype Fim2. Increases 
in  the  incidence  of  pertussis  have  been  reported 
in many countries with a long vaccination history. 
Moreover,  in  many  of  these  countries  divergence 
between vaccine strains and circulating isolates has 
been detected. Interestingly, the incidence of pertus-
sis has been decreasing in Serbia. It is known that 
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can be mild and patients do not usually seek medical 
help. Therefore, the possibility that the incidence of 
pertussis is underestimated in this country cannot 
be excluded. Whether the low incidence of pertussis 
in this country is related to the vaccine used remains 
to be confirmed. King et al. (2001) were the first to 
show that variation in Prn affects vaccine efficacy in 
the mouse model. It has been recently shown that 
the  adequate  bacterial  elimination  rates  were  ob-
served in mice immunized and challenged with the 
same vaccine type strain (Bottero et al., 2007), and 
that the vaccine prepared from a recent isolate pro-
vided the highest mouse protection when compared 
to those prepared from the old isolates, such as the 
strain Tohama I (Pereira et al., 2005). The question 
of  whether  prn2  strains  eventually  became  pre-
dominant in this country remains to be uncovered 
in further investigations. According to the observed 
findings, the B. pertussis population in Serbia is dif-
ferent from other vaccinated populations, and this 
difference may be related to the vaccine used.
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